Middle East Healthcare Past Earnings Performance
Past criteria checks 4/6
Middle East Healthcare has been growing earnings at an average annual rate of 20.8%, while the Healthcare industry saw earnings growing at 20.3% annually. Revenues have been growing at an average rate of 13.8% per year. Middle East Healthcare's return on equity is 12.1%, and it has net margins of 7.4%.
Key information
20.8%
Earnings growth rate
20.8%
EPS growth rate
| Healthcare Industry Growth | 12.3% |
| Revenue growth rate | 13.8% |
| Return on equity | 12.1% |
| Net Margin | 7.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
With EPS Growth And More, Middle East Healthcare (TADAWUL:4009) Makes An Interesting Case
Dec 16
Investors Will Want Middle East Healthcare's (TADAWUL:4009) Growth In ROCE To Persist
Sep 24Middle East Healthcare Company (TADAWUL:4009) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Aug 09Middle East Healthcare Company's (TADAWUL:4009) Price In Tune With Earnings
Jul 18There's Been No Shortage Of Growth Recently For Middle East Healthcare's (TADAWUL:4009) Returns On Capital
May 30Middle East Healthcare Company Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 09If EPS Growth Is Important To You, Middle East Healthcare (TADAWUL:4009) Presents An Opportunity
Apr 29Why Investors Shouldn't Be Surprised By Middle East Healthcare Company's (TADAWUL:4009) 27% Share Price Plunge
Apr 02There's Reason For Concern Over Middle East Healthcare Company's (TADAWUL:4009) Massive 40% Price Jump
Feb 11Returns On Capital At Middle East Healthcare (TADAWUL:4009) Have Stalled
Feb 08Should You Be Adding Middle East Healthcare (TADAWUL:4009) To Your Watchlist Today?
Jan 18Middle East Healthcare Company's (TADAWUL:4009) Revenues Are Not Doing Enough For Some Investors
Dec 28Middle East Healthcare (TADAWUL:4009) Will Want To Turn Around Its Return Trends
Sep 26Some Investors May Be Worried About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Jun 28Investors Could Be Concerned With Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Mar 30Capital Allocation Trends At Middle East Healthcare (TADAWUL:4009) Aren't Ideal
Sep 20Calculating The Intrinsic Value Of Middle East Healthcare Company (TADAWUL:4009)
Jun 14Returns On Capital At Middle East Healthcare (TADAWUL:4009) Paint A Concerning Picture
Apr 18Here's What's Concerning About Middle East Healthcare's (TADAWUL:4009) Returns On Capital
Aug 10Middle East Healthcare (TADAWUL:4009) Will Will Want To Turn Around Its Return Trends
Mar 29An Intrinsic Calculation For Middle East Healthcare Company (TADAWUL:4009) Suggests It's 28% Undervalued
Mar 03Are Middle East Healthcare's (TADAWUL:4009) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 10Weak Financial Prospects Seem To Be Dragging Down Middle East Healthcare Company (TADAWUL:4009) Stock
Jan 23If You Had Bought Middle East Healthcare's (TADAWUL:4009) Shares Three Years Ago You Would Be Down 38%
Jan 05Should You Be Impressed By Middle East Healthcare's (TADAWUL:4009) Returns on Capital?
Dec 18Calculating The Fair Value Of Middle East Healthcare Company (TADAWUL:4009)
Nov 30Revenue & Expenses Breakdown
How Middle East Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,854 | 211 | 689 | 0 |
| 30 Jun 24 | 2,793 | 203 | 668 | 0 |
| 31 Mar 24 | 2,704 | 182 | 654 | 0 |
| 31 Dec 23 | 2,653 | 180 | 661 | 0 |
| 30 Sep 23 | 2,551 | 177 | 603 | 0 |
| 30 Jun 23 | 2,393 | 135 | 574 | 0 |
| 31 Mar 23 | 2,276 | 105 | 551 | 0 |
| 31 Dec 22 | 2,152 | 75 | 532 | 0 |
| 30 Sep 22 | 2,033 | 24 | 547 | 0 |
| 30 Jun 22 | 2,019 | 27 | 569 | 0 |
| 31 Mar 22 | 1,968 | 26 | 565 | 0 |
| 31 Dec 21 | 1,873 | 17 | 541 | 0 |
| 30 Sep 21 | 1,823 | 45 | 493 | 0 |
| 30 Jun 21 | 1,816 | 66 | 474 | 0 |
| 31 Mar 21 | 1,733 | 73 | 438 | 0 |
| 31 Dec 20 | 1,751 | 82 | 454 | 0 |
| 30 Sep 20 | 1,708 | 110 | 443 | 0 |
| 30 Jun 20 | 1,603 | 108 | 400 | 0 |
| 31 Mar 20 | 1,583 | 104 | 399 | 0 |
| 31 Dec 19 | 1,497 | 98 | 360 | 0 |
| 30 Sep 19 | 1,401 | 91 | 341 | 0 |
| 30 Jun 19 | 1,353 | 78 | 344 | 0 |
| 31 Mar 19 | 1,346 | 100 | 335 | 0 |
| 31 Dec 18 | 1,391 | 172 | 326 | 0 |
| 30 Sep 18 | 1,445 | 224 | 317 | 0 |
| 30 Jun 18 | 1,459 | 269 | 304 | 0 |
| 31 Mar 18 | 1,464 | 297 | 300 | 0 |
| 31 Dec 17 | 1,462 | 319 | 297 | 0 |
| 30 Sep 17 | 1,503 | 322 | 342 | 0 |
| 30 Jun 17 | 1,529 | 356 | 372 | 0 |
| 31 Mar 17 | 1,588 | 368 | 426 | 0 |
| 31 Dec 16 | 1,616 | 363 | 466 | 0 |
| 30 Sep 16 | 1,629 | 380 | 462 | 0 |
| 30 Jun 16 | 1,602 | 371 | 448 | 0 |
| 31 Mar 16 | 1,564 | 389 | 425 | 0 |
| 31 Dec 15 | 1,535 | 390 | 418 | 0 |
| 30 Sep 15 | 1,485 | 373 | 413 | 0 |
| 30 Jun 15 | 1,456 | 356 | 424 | 0 |
| 31 Mar 15 | 1,431 | 357 | 405 | 0 |
| 31 Dec 14 | 1,399 | 332 | 424 | 0 |
| 31 Dec 13 | 828 | 137 | 285 | 0 |
Quality Earnings: 4009 has high quality earnings.
Growing Profit Margin: 4009's current net profit margins (7.4%) are higher than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4009's earnings have grown significantly by 20.8% per year over the past 5 years.
Accelerating Growth: 4009's earnings growth over the past year (19.5%) is below its 5-year average (20.8% per year).
Earnings vs Industry: 4009 earnings growth over the past year (19.5%) exceeded the Healthcare industry 13.5%.
Return on Equity
High ROE: 4009's Return on Equity (12.1%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:06 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Middle East Healthcare Company is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ibrahim Elaiwat | Aljazira Capital Company |
| Jassim Al-Jubran | Aljazira Capital Company |
| Madhu Appissa | Al Rajhi Capital |